Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)

{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4917901-merck-kgaa-bio-techne-acquisition-improves-quality-but-stock-seems-fully-valued-downgrade"},"author":{"@type":"Person","name":"Wolf Report","url":"https://seekingalpha.com/author/wolf-report"},"publisher":{"@context":"https://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…

Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.